ALLK 外匯新聞
Allakos Says Phase 3 Study Of Lirentelimab In EoD Missed Symptomatic Co-primary Goal
Biotechnology company Allakos Inc. (ALLK) on Friday reported data from EoDyssey, a 24-week, Phase 3, randomized, double-blind, placebo-controlled study of lirentelimab in patients with biopsy confirmed eosinophilic duodenitis (EoD).
RTTNews
|
856天前
